HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Daniel E Afar Selected Research

budigalimab

2/2022First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma.
1/2021Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181).
1/2021Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Daniel E Afar Research Topics

Disease

3Neoplasms (Cancer)
01/2021 - 05/2003
2Disease Progression
02/2022 - 08/2005
1Squamous Cell Carcinoma of Head and Neck
02/2022
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
02/2022
1Small Cell Lung Carcinoma (Small Cell Lung Cancer)
01/2021
1Adenocarcinoma
08/2005
1Lung Neoplasms (Lung Cancer)
08/2005
1Prostatic Neoplasms (Prostate Cancer)
05/2003

Drug/Important Bio-Agent (IBA)

3budigalimabIBA
02/2022 - 01/2021
1LigandsIBA
02/2022
1rovalpituzumab tesirineIBA
01/2021
1Programmed Cell Death 1 ReceptorIBA
01/2021
1Gefitinib (Iressa)FDA Link
08/2005
1ErbB Receptors (EGF Receptor)IBA
08/2005
1Adenosine Triphosphate (ATP)IBA
08/2005
1AndrogensIBA
05/2003

Therapy/Procedure

1Duration of Therapy
02/2022